Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Nov;119(5):931–936. doi: 10.1111/j.1476-5381.1996.tb15761.x

The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret.

J A Rudd 1, C C Jordan 1, R J Naylor 1
PMCID: PMC1915933  PMID: 8922742

Abstract

1. The anti-emetic effects of the NK1 tachykinin receptor antagonist, CP 99,994 (10 mg kg-1) were investigated in the ferret using a cisplatin-induced acute (day 1) and delayed (day 2 and 3) retching and vomiting model. 2. With a single cisplatin (10 mg kg-1) emetogenic challenge, the i.p. administration of CP 99,994 given as a single injection immediately following the first emetic episode, promptly abolished the retching and vomiting for a 4 h period. CP 99,994 was as efficacious as ondansetron (1.0 mg kg-1). The general toxicity of cisplatin 10 mg kg-1 precluded its use in studies of delayed emesis. 3. With a single cisplatin (5 mg kg-1) emetogenic challenge, the single administration of either CP 99,994 (10 mg kg-1) or ondansetron (1.0 mg kg-1) immediately following the first emetic episode markedly reduced or abolished the retching and vomiting for 4 h. Such single treatments failed to modify significantly the intensity of delayed emesis appearing on the second and third day. 4. With a cisplatin (5 mg kg-1) emetogenic challenge, administration of CP 99,994 (10 mg kg-1) at 8 hourly intervals, the first injection being administered 30 s post cisplatin, was associated with 4 or more abolitions of emesis during both the acute and delayed phase. A 4 hourly administration of CP 99,994 for 20 h during delayed emesis completely abolished the retching and vomiting. 5. It is concluded that cisplatin 5 mg kg-1 provides an emetogenic challenge causing an acute and delayed phase of retching and vomiting and that CP 99,994 can abolish both phases. The results may be relevant to the understanding and treatment of chemotherapy-induced emesis in man.

Full text

PDF
931

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beattie D. T., Beresford I. J., Connor H. E., Marshall F. H., Hawcock A. B., Hagan R. M., Bowers J., Birch P. J., Ward P. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol. 1995 Dec;116(8):3149–3157. doi: 10.1111/j.1476-5381.1995.tb15117.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Finn A. L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990 Mar 22;322(12):810–816. doi: 10.1056/NEJM199003223221204. [DOI] [PubMed] [Google Scholar]
  3. Cubeddu L. X., Hoffmann I. S. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharmacol. 1993 Aug;33(8):691–697. doi: 10.1002/j.1552-4604.1993.tb05608.x. [DOI] [PubMed] [Google Scholar]
  4. Gardner C. J., Twissell D. J., Dale T. J., Gale J. D., Jordan C. C., Kilpatrick G. J., Bountra C., Ward P. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol. 1995 Dec;116(8):3158–3163. doi: 10.1111/j.1476-5381.1995.tb15118.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Grunberg S. M. Potential for combination therapy with the new antiserotonergic agents. Eur J Cancer. 1993;29A Suppl 1:S39–S41. doi: 10.1016/s0959-8049(05)80260-6. [DOI] [PubMed] [Google Scholar]
  6. McLean S., Ganong A., Seymour P. A., Snider R. M., Desai M. C., Rosen T., Bryce D. K., Longo K. P., Reynolds L. S., Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther. 1993 Oct;267(1):472–479. [PubMed] [Google Scholar]
  7. Roila F. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination. Oncology. 1993 May-Jun;50(3):163–167. doi: 10.1159/000227171. [DOI] [PubMed] [Google Scholar]
  8. Rudd J. A., Bunce K. T., Naylor R. J. The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology. 1996 Jan;35(1):91–97. doi: 10.1016/0028-3908(95)00137-9. [DOI] [PubMed] [Google Scholar]
  9. Rudd J. A., Naylor R. J. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol. 1996 May;118(2):209–214. doi: 10.1111/j.1476-5381.1996.tb15388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Räth U., Upadhyaya B. K., Arechavala E., Böckmann H., Dearnaley D., Droz J. P., Fosså S. D., Henriksson R., Aulitzky W. E., Jones W. G. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology. 1993 May-Jun;50(3):168–172. doi: 10.1159/000227172. [DOI] [PubMed] [Google Scholar]
  11. Tattersall F. D., Rycroft W., Hill R. G., Hargreaves R. J. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology. 1994 Feb;33(2):259–260. doi: 10.1016/0028-3908(94)90018-3. [DOI] [PubMed] [Google Scholar]
  12. Tattersall F. D., Rycroft W., Marmont N., Cascieri M., Hill R. G., Hargreaves R. J. Enantiospecific inhibition of emesis induced by nicotine in the house musk shrew (Suncus murinus) by the neurokinin1 (NK1) receptor antagonist CP-99,994. Neuropharmacology. 1995 Dec;34(12):1697–1699. doi: 10.1016/0028-3908(95)00164-6. [DOI] [PubMed] [Google Scholar]
  13. Walsh D. T., Weg V. B., Williams T. J., Nourshargh S. Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol. 1995 Apr;114(7):1343–1350. doi: 10.1111/j.1476-5381.1995.tb13354.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Watson J. W., Gonsalves S. F., Fossa A. A., McLean S., Seeger T., Obach S., Andrews P. L. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995 May;115(1):84–94. doi: 10.1111/j.1476-5381.1995.tb16324.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wilder-Smith O. H., Borgeat A., Chappuis P., Fathi M., Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer. 1993 Oct 1;72(7):2239–2241. doi: 10.1002/1097-0142(19931001)72:7<2239::aid-cncr2820720729>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES